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T-LYMPHOCYTOT0XICITY IN MALIGNANT ~:
INDUCTION WITH AUTO--S MUTAGI~NIZED TUMOR CELL CLONES A.Knuth, A.van Pel*, K.-H.Meyer ZLTa Bueschenfelde, and T.Boon* Mutagentreatment of spontaneous non-J/rmunogenicmouse ttTnors induces variants that elicit a strong rejection response in syngeneic mice. The rejection response is due to so-called t~n-antigens regcx]nized by cytolytic T-l}~llohocytes (CTL). After rejection of t um tumor cell clones, ITLiCe show a cert~n degree oz resistance against a challe~qe with the original non-mutagenized timer cells (tL~nt). Our study was to investigate if thins phenomenon of iirmune protection would have relevance in human cancer ~munotnerapy. Melanoma cells from a 38 year old patient with metastatic melanoma were ad&pted to ~issue .culture (MZ-MEL-2), clonea ana repeat-edlymutagenizeain vitro with mutage_nic compounQs. After several intracutaneous ir~nuf/zations with lethally irradiated mutagenized autologous tt~nor cell clones peripneral blc6d mononuclear cells (PBL) were cultured in vitro with these melan.ana clones, e xp@nded in IL-2 containing culture meoiL~nand tested for cytolytic activityano specificity in vitro. Strong CTLactivity directed against the autologous melanoma cells, Put not I~pstein-Barr-virus transformed autologous B-lymphocyte cultures, K562 cells or alloqeneic melanoma tarqets was seen. Mutagenized as well as non-mutagenized autolggous melanclna target cells were lynCh. The specizlcizy oz non-cloned CTLwas conzirmea in competitive inhibition assays. We are presently investigating, if CTL bulk cultures or CTL c• after coculture with different mutaqenizeo auto• tumor cell clones will preferentially l~se a single tLm~Dr clone, ana+not the non-mutagenlzea original tt~nor cells (tt~n). This would be the evidence of a For the short-term metabolic assay extensive claims have been made as to its general applicability as a predictive test, although only two drugs are used to indicate sensitivity or resistance. This contrasts sharply with findings of other investigators who describe unique chemosensitivity patterns in xenografted human tumors (I).
We have exposed 3 human melanoma xenografts to "alkylating agents and adriamycin and compared tumor growth curves to results from short-term assays performed on these xenografts. 'Str' is about
• more sensitive to dacarbazine than 'Grll' and may be cured by intermediate doses of methyl-CCNU. Adriamycin is only very weakly effective against this tumor, and an activated form of cyclophosphamide, mafosfamide (ASTA Z ?55?), induces some growth delay. MethyI-CCNU, mafosfam-• and adriamycin were totally ~neffective against melanoma '3aI', although the latter line is somewhat sensitive to dacarbazine. ~aking a 50~ inhibition of 3N-uridine (or H-thymidine) incorporation as a cutoff-point, tumor line 'Str' was correctly classified as sensitive to methyl-CCNU and mafosfamide but falsely as sensitive to adriamycin.
All three drugs were falsely classified as effective for completely resistant melanoma 'GrII', and for line '3aI' 0nly resistance to methyl-CCNU was indicated correctly by the short-term assay. Therefore. the limitation of predictive testing to one or two key antineoplastic drugs is not warranted by the heterogeneity present even among human tumors of similar histiogenetic origin. {I) 0sieka, R: Primary and acquired resistance to anti- This study was designed to assess the value of chemotherapy vs. immunotherapy in high risk melanoma after surgical removal of a primary malignant melanoma of the skin. Eligibility criteria included the following conditions: previously untreated, histologically confirmed, primary cutaneous malignant melanoma of Clark stage Ill, IV, V with a Breslow's thickness equal or exceeding 1,5 mm, no evidence for lymphnode metastases. 0nly melanoma of the extremities were submitted to elective lymphnode dissection. Randomization for 3 arms was done between DTIC and immunotherapy plus placebo. DTIC (250mg/m 2 b.s./dayx5, q4w) was given for a total of 6 cycles. Levamisole or placebo was taken orally on 2 consecutive days every week for 2 years (150-250 mg tablets per day according to weight). Results: 235 patients were entered and 94 considered as ~le.
Subgroup analysis reveals that the 96 limb melanoma patients did better than the 172 head, neck, and trunk patients: 5 years DFI 70% vs. 45% and 5 years S 75% vs. 50% resp. This highly significant difference may be due in part to the histological selection of node-negative patients for limb melanoma. 107 out of 276 eligible patients reported a progression, which was local in 19, regional in 47 and distant in 41 patients. Toxicity has been acceptable but higher in the DTIC arm where more protocol violations occured. This report indicates that neither DTIC for 6 months not Levamisole for 2 years had any effect on disease free interval (DFS) or survival (S) of patients with high risk primary melanoma. Haemat.-onkol. Praxis Altona, 2000 Hamburg 50, Germany Secretariat of the EORTC Malignant Melanoma Coop. Group
